Dapsone therapy for Henoch-Schönlein purpura: a case series
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Comment on: Dapsone therapy for Henoch-Schonlein purpura: a case series
    • Jae Seung Lee, Pediatric Nephrologist, Professor
    • Other Contributors:
      • Jae Il Shin, Ki Seop Chung

    Dear Editor,

    We read with interest an article on Dapsone therapy for Henoch-Schonlein purpura: a case series by Iqbal et al.[1] They reported the clinical course of 8 children with Henoch-Schonlein purpura (HSP) treated with dapsone due to the severity or persistence of their symptoms. All gained clinical response from treatment, but six of eight relapsed after treatment was stopped and nephritis was observed in fi...

    Show More
    Conflict of Interest:
    None declared.